FSHR Inhibitors
2 drugsAbout FSHR
The follicle-stimulating hormone receptor (FSHR) is a G protein-coupled receptor crucial for reproductive physiology. As the primary receptor for follicle-stimulating hormone (FSH), it is essential for gonadal development and function in both females and males.
FSHR's established physiological importance makes it a significant target for drug development. Currently, there is no genetic evidence data available linking FSHR to specific diseases.
Two drugs targeting FSHR have been approved: GONAL-F RFF and GONAL-F RFF REDI-JECT, both biologics. These drugs, developed by EMD SERONO, are used in specific therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Insemination with only 1 trials.
Top Drugs
EMD SERONO is the only company with approved drugs targeting FSHR.
The lack of competitors suggests high barriers to entry or an underserved market.
Drug Modality Landscape
Modalities
Routes of Administration
FSHR requires biologic approaches (enzyme), likely due to its structure or location.
Explore small molecule or alternative modalities to differentiate from existing FSHR-targeting therapies.
Clinical Trials 91 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 22 | 19 | 2 | 1 | 90% |
| Phase 2 | 15 | 13 | 0 | 2 | 100% |
| Phase 3 | 30 | 30 | 0 | 0 | 100% |
| Phase 4 | 24 | 16 | 4 | 4 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2004 - 2004)
The first FSHR-targeting drug was approved in 2004, with the most recent approval also in 2004.
The stagnant approval timeline indicates a mature market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 48 clinical trials targeting FSHR.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities